| Methods |
Randomised controlled trial, single‐blind |
| Participants |
Patients with neutropenia < 1000/mm3, fever > 38
Mean age 45 (9‐82) yrs, with all types of cancer |
| Interventions |
Trimethoprim/sulphamethoxazole 2.5 mg/kg x 4 (max 640 mg per day) added to one arm
Non‐intervention antibiotics: piperacillin + amikacin |
| Outcomes |
Failure
Mortality (all‐cause and infection‐related)
Superinfections
Adverse events |
| Notes |
Empirical design
Single centre, Italy |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Random sequence generation (selection bias) |
Low risk |
Table of random numbers |
| Allocation concealment (selection bias) |
Unclear risk |
Sealed envelopes (opacity not mentioned) |
| Blinding of participants and personnel (performance bias)
All outcomes |
Unclear risk |
Single‐blind |
| Blinding of outcome assessment (detection bias)
All outcomes |
High risk |
|
| Incomplete outcome data (attrition bias)
All outcomes |
High risk |
|
| Other bias |
High risk |
Patients included for different episodes and analysis by episode |
